Investor Relations

Press Releases

Date Title  
Toggle Summary JPLs release copy of their Eleventh Report to the Grand Court of the Cayman Islands
Toggle Summary On 10 February 2025, the JPLs issued their second fee report relating to fees and disbursements for the period 1 October 2023 to 30 September 2024. Please click here to access a letter from the JPLs dated 11 February 2025 to purported shareholders providing notice of the fee report, the JPLs’ intention to provide a copy to any shareholder who is able to evidence their holding, and the JPLs’ intention to obtain Court sanction of the fees described therein
Toggle Summary JPLs release copy of their Tenth Report to the Grand Court of the Cayman Islands
Toggle Summary JPLs release copy of their Ninth Report to the Grand Court of the Cayman Islands
Toggle Summary The JPLs summons (as amended) was part-heard on 30 July 2024 and resulted in various orders by the Grand Court of the Cayman Islands. On 9 August 2024, a notice was issued to shareholders providing, inter alia, details of the outcome of the hearing, together with a copy of the Court orders.
Toggle Summary On 18 July 2024, the JPLs issued correspondence to shareholders providing notice of an amendment to the Summons to seek Court approval of the proposed terms of remuneration. A sealed version of the amended summons was received from the Court Registry on 17 July 2024. Please click here for a copy of the notice and the Court orders
Toggle Summary JPLs release copy of their Eighth Report to the Grand Court of the Cayman Islands
Toggle Summary i. On 13 May 2024, the JPLs filed a summons for court approval of the terms of their remuneration agreement and their remuneration for the Fee Approval Period pursuant to section 109(2) of the Companies Act and the Insolvency Practitioners' Regulations (2023 Consolidation) (the "Summons"). The Summons has been listed for hearing at 10am on 30 July 2024.
ii. Any shareholder who wishes to provide any additional comments or queries regarding the JPLs' proposed terms of remuneration and the JPLs' remuneration for the Fee Approval Period should do so in writing to the JPLs by no later than 1 July 2024. Any communications should be sent by email to [email protected].
iii. Any shareholder who intends to appear at the hearing of the Summons must notify the JPLs and confirm whether they support or oppose the orders being sought by no later than 9 July 2024 so as to ensure that the hearing of the Summons proceeds in an orderly manner.
Toggle Summary JPL's announce EGM to be held on 16 April 2024 for the purpose of considering and, if thought fit, passing resolutions in respect to the JPL's proposed terms of remuneration and the JPL's remuneration and disbursements for the period from 22 September 2022 to 30 September 2023. Further details regarding the proposals are set out in the i) Notice of EGM ii) Proxy Card iii) Proxy Statement and iv) Rules of Conduct. Note that only verified shareholders will be able to vote at the EGM.
Toggle Summary JPLs release copy of their Seventh Report to the Grand Court of the Cayman Islands
Toggle Summary JPLs release copy of their Sixth Report to the Grand Court of the Cayman Islands
Toggle Summary JPLs release copy of their Fifth Report to the Grand Court of the Cayman Islands
Toggle Summary JPLs release copy of their Fourth Report to the Grand Court of the Cayman Islands
Toggle Summary JPLs release copy of their Third Report to the Grand Court of the Cayman Islands
Toggle Summary JPLs release copy of their Second Report to the Grand Court of the Cayman Islands
Toggle Summary JPLs release copy of their First Report to the Grand Court of the Cayman Islands
Toggle Summary Press Release in respect of the JPLs appointment
Toggle Summary Global Cord Blood Corporation Files Annual Report on Form 20-F
Toggle Summary Global Cord Blood Corporation Obtained Injunction Order Against Blue Ocean in respect of Purported EGM
Toggle Summary Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2022
Toggle Summary Global Cord Blood Corporation Announced Cellenkos Receives FDA Clearance of IND Application for CK0804 as Add on Therapy to Ruxolitinib for the Treatment of Myelofibrosis
Toggle Summary Global Cord Blood Corporation Announces Purported EGM Is Not Validly Convened
Toggle Summary Global Cord Blood Corporation Announces Receipt of Blue Ocean Petition
Toggle Summary Global Cord Blood Corporation Announces Entry into Cell Therapy Market by Acquiring Cellenkos and Its Products Rights
Toggle Summary Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2022
Toggle Summary Global Cord Blood Corporation to Report Third Quarter and First Nine Months Fiscal 2022 Financial Results

About GCBC

Services

Investor Relations

About Cord Blood Banking

Copyright © 2022 Global Cord Blood Corporation. All rights reserved.
Sitemap     |    Terms of Use